Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen

The management of hepatotoxicity during treatment with H mono/poly Drug-resistant TB (DR-TB) regimen is elaborated in the figure below.

Figure: Management of hepatotoxicity during treatment with H mono/poly DR-TB regimen; Source: Guidelines for PMDT, India 2021, p89.

Abbr: AST: Aspartate aminotransferase; ALT: Alanine transaminase; FQ: Fluoroquinolone; R: Rifampin; Z: Pyrazinamide; UNL: Upper Normal Level

Resources

• Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021.
• WHO Consolidated Guidelines on Tuberculosis: Module 4 - Treatment: Drug-resistant TB Treatment, 2020.
• Technical and Operational Guidelines for TB in India, 2016.

Kindly provide your valuable feedback on the page to the link provided HERE